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Abstract: Aptamers are artificial oligonucleotides (DNA or RNA) selected in vitro that 
bind a broad range of targets with high affinity and specificity; a sensitive yet simple 
method to utilize aptamers as recognition elements for the development of biosensors 
(aptasensors) is to transduce the signal electrochemically. So far, aptasensors have been 
applied to clinical diagnostics and several technologies are in development. Aptasensors 
will extend the limits of current clinical diagnostics. Although the potential diagnostic 
applications are unlimited, the most current applications are foreseen in the areas of 
biomarker detection, cancer clinical testing, detection of infectious microorganisms and 
viruses. This review attempts to list examples of the research progresses of aptamers in 
biosensor platforms that have been published in recent years; in particular, we display 
cases of aptasensors that are already incorporated in clinical diagnostics or have potential 
applications in clinical diagnostics. 
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1. Introduction  
High requirements regarding human health have resulted in an increasing number of   
clinical tests, so there is a rising need to develop more sensitive, reliable, time-efficient and 
inexpensive methods of analysis. Conventional techniques, such as molecular assays (immunological 
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or nucleic acid technologies) and microbial culture-based tests, are either time consuming or require 
sophisticated equipment and expensive. Biosensor technology is probably one of the fastest growing 
areas to solve some of the problems concerning sensitive, rapid and cheap measurement [1]. 
A biosensor is defined as a compact analytical device incorporating a molecular recognition entity 
associated with or integrated with a physicochemical transducer [2]. It consists of two main components, 
a biological component, which reacts with a target substance, and a signal-generating component, which 
detects the resulting products. More specifically, we can consider a biosensor as a type of biomolecular 
probe that weighs the presence or concentration of biological molecules or biological structures by 
translating a biochemical interaction at the probe surface into a quantifiable physical signal. Biosensors 
are already used for several clinical applications, such as for electrochemical measurement of blood 
glucose concentrations. The first generation of biosensors were catalytic systems that integrated 
particularly enzymes with transducers that transferred the biological reaction into an electronic signal. 
The next generation of biosensors, affinity biosensors, utilized different biological elements, such as 
antibodies, receptors (natural or synthetic). Furthermore, the reaction between the target and the 
immobilized biomolecule on the transduction element is controlled by affinity interactions, such as the 
antigen-antibody, the DNA-DNA. 
Recognition molecules are the key element of biosensors since the sensitivity and specificity of  
the sensing elements will play an important role in the success of the sensor device [3]. A range of 
recognition molecules have been employed for clinical diagnosis. However, the use of antibodies in 
biosensor detection methods and in the analysis of very complex samples could partially be hampered 
by the nature and synthesis of these protein receptors. In order to circumvent some of these drawbacks, 
other recognition molecules, such as aptamers, are being explored as alternative. This review attempts 
to list examples of the research progress of aptamers in biosensor platforms that have been published 
in recent years; in particular, we display cases of aptasensors that are already incorporated in clinical 
diagnostics or have potential applications in clinical diagnostics. 
2. Aptasensors 
2.1. Aptamers and Biosensors  
Aptamers (derived from the latin aptus, meaning to fit) are artificial nucleic acid (DNA or RNA) 
ligands which can be selected from combinatorial libraries of synthetic nucleic acids, possessing 
specific binding characteristics to their targets. Using the systematic evolution of ligands (SELEX) 
process, aptamers can be isolated from randomly synthesized RNA or DNA pools and produced. 
Numerous high-affinity and highly specific aptamers have been generated against a wide variety of 
target molecules including small organics, peptides, proteins, and even complex-target such as whole 
cell [4,5]. In addtion, aptamers can be selected against non-immunogenic and toxic targets, which 
make the technique superior to antibodies, enabling the design and synthesis of probes or capture 
molecules for such targets.  
Biosensors that employ aptamers as a recognition element are called aptasensors [6]. DNA and 
RNA aptamers can be modified chemically to undergo analyte-dependent conformational changes. For 
instance, Aptamers can be modified for immobilization purposes and incorporated particular reporters, Sensors 2012, 12                              
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without influencing their affinity, which has aided varieties of design methods [7–12]. Aptamers can 
also be engineered to withstand repeated cycles of denaturation and renaturation; this opens up a 
possibility to regenerate the immobilized biocomponent function for reuse [6,13]. In addition, they can 
be easily labeled for their use in diagnostics [14].  
2.2. Signal-Transduction 
Development of aptasensors has been carried out with various detection schemes, from   
label-free methods, such as surface plasmon resonance (SPR) [15], and quartz crystal microbalance 
(QCM) measurements, to other methods often requiring labels, such as electrochemistry[16], 
fluorescence [17–19], chemiluminescence [20], field effect transistors [10,16], which have been 
reported and enhanced the advancement of this field. Alternatively, sensors often utilize labeled target 
molecules or secondary capture agents (in the case of a sandwich-type assay) which themselves 
contain some forms of label or reporter molecule. So far, there are mainly two types of aptasensors to 
apply, including electrochemical and optical aptasensors. 
2.2.1. Electrochemical Aptasensors 
A typical electrochemical aptasensor makes use of an electrode surface as the platform to immobilize 
biological sensing aptamer, for which the analyte-binding event is monitored based on electrochemical 
current variations. Electrochemical transduction offers the advantages of high sensitivity, which can  
be enhanced by attaching biocatalytic labels to the aptamer-target complexes to amplify the detection 
signal, readily miniaturized, and low cost of production since they do not require expensive optical 
instruments [16,21]. Additionally, it is possible to use label-free and reusable detection systems. 
2.2.2. Optical Aptasensors 
Optical aptasensors include aptamers labeled with fluorescence, luminophore, enzyme, nanoparticles) 
or aptamer with label-free detection systems (e.g., SPR, optical resonance) [22]. Most methods are 
mainly based on a labeling approach. Some targets can be optically detected using not only colorimetry, 
chemiluminescence or the most developed fluorescence mode but also more recent non-conventional 
optical methods such as surface plasmon-coupled directional emission (SPCDE) [22]. 
Different label-free techniques have recently been shown to be suitable for developing aptasensors 
or aptamer-based microarrays, such as surface plasmon resonance (SPR), diffraction grating, 
evanescent-field-coupled (EFC) waveguide-mode, optical resonance or Brewster angle straddle 
interferometry (BASI) [22]. SPR biosensors prepared using optical fibers can be used as a cost-effective 
and relatively simple-to-implement alternative to well established biosensor platforms for monitoring 
biomolecular interactions in situ or possibly in vivo [23]. 
3. Application of Aptasensors in Clinical Diagnosis 
Beyond all these features, the applications of aptamers as bio-compotents have offered extraordinary 
prospects in diagnostic assays [24]. Here we briefly describe a few examples of the use of aptasensors in 
the areas of biomarker detection, cancer clinical testing, and detection of infectious microorganisms. Sensors 2012, 12                              
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3.1. Application of Aptasensors for Detection of Biomarkers 
The analysis of biomarkers in blood, urine and other body fluids is one of the methods applied in the 
early detection of diseases. Aptasensors have been used for detection of biomarkers, such as thrombin, 
Immunoglobulin (Ig) E. A list of examples of the available reports of aptasensors for different 
biomarkers is provided in Table 1. Furthermore, representative examples of aptasensors for detection 
of thrombin are discussed in the following section. 
Table 1. Examples of application of aptasensors for detection of biomarkers. 
Target 
biomarker 
Aptamer  Detection type 
Signal 
transduction 
Linear range/ 
LOD 
Reference 
Thrombin 
DNA labeled with the 
HCoPt-RGs conjugates 
Sandwich-type  Electrochemical 
1.0 × 10
−12 to  
5.0 × 10
−8 M/ 
3.4 × 10
−13 M 
Wang et al. 
(2011) [25] 
Thrombin 
DNA dual labeled with 
AuNPs and HRP 
Sandwich-type  Electrochemical 
0.1 to 60 pM/ 
30 fM 
Zhao et al. 
(2011) [26] 
Thrombin  DNA  Label free detection  Fluorescence 
0 to 0.02 μM/ 
0.1 nM 
Pu et al. 
(2009)[27] 
Thrombin 
DNA labeled with a 
hole injector, 
naphthalimide, and a 
flurophore, Alexa532 
DNA charge 
transport 
Fluorescence 
5 pM to 5 nM/ 
1.2 pM 
Zhang et al. 
(2011) [28] 
Thrombin 
DNA SA-ALP and 
biotinylated labled 
Sandwich-type  ECL 
1 × 10
−15 to 1 × 10
−8 M/ 
0.33 fM 
Liao et al. 
(2011) [29] 
IgE 
DNA streptavidin 
labled 
ELISA-like array  SPR 
n.s./ 
n.s. 
Wang et al. 
(2008) [30] 
IgE 
DNA labeled with 
avidin monolayer 
Direct detection 
QCM 
chemiluminescence 
2.5 to 200 μg L
−1/ 
2.5 μg L
−1 
Yao et al. 
(2009) [31] 
IgE 
DNA labeled with 
single PPy nanowire-
based microfluidic 
One step 
electrochemical 
deposition method 
Electrochemical 
0.1 to 100 nM/ 
0.01 nM 
Huang et al. 
(2011) [32] 
IgE 
DNA attached to 
carboxyl (COOH)-
modified NCD surface 
Direct and  
label-free detection 
EIS 
0.03 to 42.8 mug/mL/ 
0.03 mug/mL 
Tran et al. 
(2011) [33] 
RBP4  single-stranded DNA  Label free detection  SPR 
0.2 to 0.5 μg mL
−1/ 
75 nM 
Lee et al. 
(2008) [34] 
CRP  RNA biotinylated  Direct detection  Optical 
n.s./ 
0.005 ppm 
Bini et al. 
(2008) [35] 
CRP  DNA  Sandwich-type  Optical 
10 microg/L to 100 mg/L/ 
n.s. 
Pultar et al. 
(2009) [36] 
NT-proBNP 
DNA with  
cocaine-binding 
Sandwich-type  ECL 
0.01 to 500 ng mL
−1/ 
0.77 pg mL
−1 
Mao et al. 
(2011) [37] 
IFN gamma 
DNA thiolated/ 
MB redox tag 
Direct detection  Electrochemical 
10 nM/ 
0.06 nM 
Liu et al. 
(2011) [38] 
Abbreviations: LOD, limit of detection; HCoPt-RGs, hollow CoPt alloy nanoparticle onto reduced graphene oxide sheet;  
AuNP, Au nanoparticles; HRP, horseradish peroxidase; IgE, Immunoglobulin E; QCM, quartz crystal microbalance;  
SPR, surface plasmon resonance; PPy, polypyrrole ; EIS, Electrochemical impedance spectroscopy; NCD, nanocrystalline; 
RBP4, retinol binding protein 4; CRP, C-reactive protein; NT-proBNP, N-terminal pro-brain natriuretic peptide;   
ECL, electrochemiluminescence; MB, methylene blue; IFN, interferon; n.s., not specified.  Sensors 2012, 12                              
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Thromin is an enzymatic active, circulating biomarker for blood coagulation activity levels. Clinical 
studies, applying assays and strategies applicable for endogenous plasma thrombin measurements,   
are needed to evaluate the clinical impact of thrombin. Nowadays, many assays, based on the 
thrombin-binding aptamer for the detection of thrombin, have been developed in recent years. Mostly, 
thrombin has been used as a model for detection in the aptasensors assays. The below are three cases. 
An advanced sandwich-type electrochemical aptasensor assay coupled to use the hollow CoPt alloy 
nanoparticle (HCoPt)-RGs conjugates as secondary label demonstrated a good sensitivity and selectivity, 
with a limit of detection (LOD) of 3.4 × 10
−13 M. Scheme 1 illustrates the fabrication of electrochemical 
strategy with the aptamer-linked sandwich assay for the ultrasensitive detection of thrombin. The formed 
conjugates provided large surface area for loading plentiful redox probe thionine (Thi), horseradish 
peroxidase (HRP) and secondary aptamer (Apt II) with good stability and friendly biocompatibility [25]. 
Scheme 1. Schematic diagrams of preparation of the sandwich-type electrochemical 
aptasensor and TEM images of the hollow CoPt alloy nanoparticles decorated graphene. 
Reproduced with permission form Reference [25] (Abbreviations: HT, hexanethiol; GCE, 
glassy carbon electrode; CS-HCoPt, the chitosan-hollow CoPt alloy nanoparticle). 
 
Also, a sandwich electrochemical aptasensor assay was developed for thrombin based   
on amplification of aptamer-gold nanoparticles-horseradish peroxidase (aptamer-AuNPs-HRP)   
conjugates [26]. In this electrochemical protocol, aptamer1 (Apt1) was immobilized on core/shell 
Fe3O4/Au magnetic nanoparticles (AuMNPs) and served as capture probe. Aptamer2 (Apt2) was dual 
labeled with AuNPs and HRP and used as detection probe. In the presence of thrombin, the sandwich 
format of AuMNPs-Apt1/thrombin/Apt2-AuNPs-HRP was fabricated. Remarkable signal amplification 
was realized by taking the advantage of AuNPs and catalytic reactions of HRP. Other proteins, such as Sensors 2012, 12                              
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human serum albumin, lysozyme, fibrinogen, and IgG did not show significant interference with   
the assay for thrombin. Linear response to thrombin concentration in the range of 0.1–60 pM and the 
LOD of 30 fM (S/N = 3) was obtained with the proposed method. This electrochemical aptasensor was 
simple, rapid (the whole detection period for a thrombin sample is less than 35 min), sensitive and 
highly specific, it showed promising potential in protein detection and disease diagnosis [26]. 
Meanwhile, aptasensor assays can be used for detection with various working principles. Pu et al. [27] 
have displayed a smart polymeric transducer and aptamer/intercalating dye system that allows the 
label-free detection of thrombin with high sensitivity and selectivity. Thrombin detection was 
completed through the simple “mix and detect” mode. In addition, the methodology didn’t need any 
chemical modification on the probes or the analytes. The amount of the thrombin could be measured 
by the fluorescence intensity changes. The LOD was estimated to be 0.1 nM. This strategy might  
offer a new strategy to detect a wide spectrum of analytes and would be highly beneficial in future 
clinical applications. 
3.2. Application of Aptasensors for Cancer Clinical Testing 
With the growing number of cancer cases being diagnosed worldwide, cancer is the second most 
common cause of mortality and morbidity in the World due to late disease detection. Early diagnosis is 
crucial in all cancers to improve patient survival and disease prognosis, and may lead to cancer 
prevention- and for this reason sensitive and specific methods are required for early cancer diagnosis.  
Detection and identification of tumor cells rely on the identification of some markers that appear 
only on the tumor cells such as lymphoma (Ramos) cells, leukemia cells. Identification of these cancer 
markers requires specific probes to bind in order to find the potential risk factor. In blood cells, plasma 
proteins or free DNA may be tumor markers. A number of recent studies have successfully used 
aptamers for targeting tumor markers.  
Feng et al. [39] reported an example for label-free cancer cell detection by using an electrochemical 
sensor based on the first clinical oncology trial II used aptamer AS1411 and graphene-modified electrode. 
The aptamer-PTCA (perylenetetracarboxylic acid) nanocomposite was utilized as nanoscale anchorage 
substrates to effectively capture cells on electrode surface through the specific binding between cell 
surface nucleolin and the aptamer AS1411 (Scheme 2). The electrochemical aptasensor can distinguish 
cancer cells and normal ones and detect as low as one thousand cells. With DNA hybridization 
technique, this E-DNA sensor can be regenerated and reusable for cancer cell detection.  
Platelet-derived growth factor B chain (PDGF-BB) is a potential cancer marker and is known to be 
related to tumor growth and transformation. Recently, Chai et al. [40] developed a sensitive and low 
cost ECL aptasensor for PDGF-BB by assembling N-(aminobutyl)-N-ethylisoluminol functionalized 
gold nanoparticles (ABEI-AuNPs) with aptamers as nanoprobes. The biotinylated aptamer capture 
probes were first immobilized on a streptavidin coated gold nanoparticle (AuNPs) modified electrode, 
then, a sandwich conjugate modified electrode was carried out by successively attached the target 
PDGF-BB and the ABEI-AuNPs tagged aptamer signal probe. ECL measurement was run with a 
double-step potential in carbonate buffer solution containing H2O2, showing high sensitivity and 
specificity. The detection limit was as low as 2.7 × 10
−14
 M. In addition, the ABEI-AuNPs signal 
amplification was more simple, stable, practical, and sensitive compared to other reported signal Sensors 2012, 12                              
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amplification strategies based on aptamer-related polymerase chain reaction or functionalized 
nanoparticles. Moreover, 7 human serum samples were measured by using the proposed aptasensor. 
The obtained result were in good agreement those determined by the PDGF-BB ELISA as the 
reference method, which indicated that it was feasible to apply the proposed ECL aptasensor to detect 
PDGF-BB in real human serum samples. Table 2 lists examples of aptasensors for cancer clinical 
testing in recent years.  
Scheme 2. Schematic representation of the reusable aptamer/graphene-based aptasensor. 
The sensor is constructed based on graphene-modified electrode and the first clinical   
trials II used aptamer, AS1411. AS1411 and its complementary DNA are used as a 
nanoscale anchorage substrate to capture/release cells. Reproduced with permission   
form Reference [39]. (Abbreviations: CCG, chemical converted grapheme; EDC,   
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; NHS, N-hydroxysuccinimide). 
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Table 2. Examples of application of aptasensors for cancer clinical testing. 
Cancer marker 
detected 
Aptamer  Detection type  Signal transduction 
Linear range/ 
LOD 
Reference 
HeLa cells, K562 
cells, MDA-231 cells 
DNA  Label free detection  Electrochemical 
n.s./ 
n.s. 
Feng et al. 
(2011) [39] 
PDGF-BB 
DNA labeled 
with biotin 
A sandwich conjugate 
modified electrode 
ECL 
1.0 × 10
−13 to  
1.0 × 10
−11 M/ 
2.7 × 10
−14 M 
Chai et al. 
(2011) [40] 
Ramos cancer cell, 
CEM cells 
DNA 
ECL array with a novel 
cycle-amplifying 
technique 
ECL 
n.s./ 
n.s. 
Jie et al. 
(2011) [41] 
Multi-marker or 
Ramos cells,  
CCRF-CEM cells, 
Toledo Cells  
DNA-conjugated 
FRET NP 
Simultaneous 
multiplexed analysis 
fluorescence 
n.s./ 
n.s. 
Chen et al. 
(2009) [42] 
Ramos cancer cell  DNA  Label free detection  ECL 
100 to 1,000 cells mL
−1/ 
58 cells mL
−1 
Hun et al. 
(2011) [43] 
Leukemia cells 
DNA conjugated 
apt-MBs 
a magnet-quartz 
crystal microbalance 
system 
QCM 
1 × 10
4 to  
1.5 × 10
5 cells mL
−1/ 
8 × 10
3 cells mL
−1 
Pan et al. 
(2010) [44] 
PSA 
DNA labeled 
with FITC 
Aptamer blotting 
assay 
Chemiluminescence 
40 to 100 nM/ 
n.s. 
Savory et al. 
2010 [45] 
MUC1 
DNA labeled 
with single PPy 
nanowire-based 
microfluidic 
One step 
electrochemical 
deposition method 
Electrochemical 
n.s./ 
2.66 nM 
Huang et al. 
(2011) [33] 
MUC1 
DNA labeled 
with QD 
Aptamer-based 
detection with 
quantum-dot based 
fluorescence readout 
Fluorescence 
n.s./ 
250 nM  
Cheng et al. 
(2009) [46] 
GSH  RNA 
SPR analysis and 
isocratic affinity 
chromatography 
SPR 
n.s./ 
n.s. 
Bala et al. 
(2011) [47] 
VEGF 
RNA conjugated 
CPNTs 
FET-type biosensor 
based on  
CPNTs-aptamer  
Electrochemical 
n.s./ 
400 fM 
Kwon et al. 
(2010) [48] 
Abbreviations: PDGF-BB, platelet-derived growth factor B chain; PSA, prostate specific antigen; MUC1, Mucin 1;   
FRET NP, fluorescence resonance energy transfer nanoparticles; GSH, Glutathione; SPR, surface plasmon resonance; 
ECL, electrogenerated chemiluminescence; QD NCs, quantum dot nanoclusters; VEGF, Vascular Endothelial Growth 
Factor; CPNTs, carboxylated polypyrrole nanotubes; FET, field-effect transistor; QCM, quartz crystal microbalance;   
apt-MBs, conjugated magnetic beads; QD, quantum dot; n.s., not specified. 
3.3. Aptasensors for Detection of Microorganisms and Viruses 
Detection, identification and quantification of microbial pathogens are crucial for public health 
protection. Similarly, identification of virally infected cells is essential for the study of the mechanism Sensors 2012, 12                              
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of viral diagnosis. Virus-infected cells display certain viral proteins, which are detected using probes 
for the detection of infection. Up to date, the ability to design probes for specific viral targets on the 
host cell surface is very limited. Several aptasensors have been developed to detect microorganisms 
and viral proteins. One representative example of HIV-1 Tat aptamers developed for detection is 
discussed in the following part. In addition, Table 3 lists examples of aptasensors for detection of 
microorganisms and viruses. 
Table 3. Examples of application of aptasensors for detection of microorganisms and viruses. 
Microbial and 
viral targets 
Aptamer  Detection type 
Signal 
transduction 
Linear range/ 
LOD 
Reference 
Bacillus 
thuringiensis 
DNA 
Aptamer-functionalized 
QDs 
Fluorescence 
n.s./ 
1,000 CFU/mL 
Ikanovic et al. 
(2007) [49] 
E. coli DH5a  DNA 
Aptamer-functionalized 
SWNT-FET arrays 
Fluorescence 
n.s./ 
n.s. 
So et al. 
(2008) [50] 
HIV-1 Tat  RNA biotinylated 
A QCM -based and an 
SPR-based biosensor 
QCM 
SPR 
QCM (0–1.2 ppm) 
SPR (0–2.5 ppm)/ 
QCM (0.25 ppm)  
Tombelli et al. 
(2005) [51] 
HCV core antigen  RNA  Chip-based detection  Fluorescence 
n.s./ 
n.s. 
Lee et al. 
(2007) [52] 
Prion  RNA  3-dimensional analysis  Fluorescence 
n.s./ 
n.s. 
Mashima et al. 
(2009) [53] 
Abbreviations: QD, quantum dots; CFU, colony forming units; SWNT-FET, single-walled carbon nanotube field-effect 
transistor; QCM, quartz crystal microbalance; SPR, surface plasmon resonance; n.s., not specified. 
Microgravimetric methods on piezoelectric quartz crystals are based on the change of the oscillation 
frequency of the crystal upon mass change at its surface owing to receptor-target binding (QCM). 
Then, this change of oscillation frequency is the signal that is detected. With this method, a label-free 
detection of the target is possible. Tombelli et al. [51] developed an aptasensor platform to detect  
HIV-1 Tat protein by immobilizing an RNA aptamer on a piezoelectric quartz crystal. The QCM-based 
aptasensor has also been compared with the corresponding SPR-based aptasensor. The two aptasensors 
were constructed using biotin–avidin linking onto the gold surface of the transducers (quartz crystals 
or chips) for the immobilization chemistry. Both platforms showed similar reproducibility, sensitivity 
and specificity. The linear range of SPR (1–2.5 ppm) was higher that of QCM (0–1.25 ppm) [51].  
4. Conculsions 
Aptamer science has now reached maturity, through its growing impact on biology and medicine. The 
therapeutic use of aptamers is now well established, as in December 2004 the first aptamer compound 
named Pegaptanib was approved for clinical use [54]. Conversely, the different fields of clinical 
diagnostics, when dealing with systems based on biomolecular interactions, are still under the 
supremacy of immunoassays but diagnostics studies are now showing that some of the limits of current 
clinical diagnostics can be circumvented by taking advantage of the differences between aptamers and 
antibodies, such as cost-effective synthesis, flexibility for signal transduction and detection [55]. The 
good news is that there are currently some more aptamers in clinical phase 2/3 trials, such as factor IXa Sensors 2012, 12                              
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(FIXa), Von Willebrand factor (Vwf). However, the potential values of those aptamers for clinical 
diagnosis have not been fully investigated. Up to now, there is still no good answers to the question 
why aptamers have not yet penetrated into the clinical laboratory [56] and only a few aptasensors for 
clinical diagnostics were described [56,57]. As long as more aptamers will be developed and specified, 
the more aptasensors promise to play an important role in the future development of diagnostic methods. 
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